- Challenging H1 performance due to unexpected regulatory issues causing manufacturing delays in certain smaller products and Amberen™ sales hampered by industry-wide challenges on Amazon.
- Amberen™ revenues weaker than anticipated.
- Less favourable product mix and increase in warehouse and distribution costs impacting gross profit growth.
- Counterfeiting and illicit trade of Kelo-Cote™ in China.
- Regulatory transition from the European Medical Device Directive (“MDD”) to the Medical Device Regulation (“MDR”) impacting supply of certain products.
Alliance Pharma plc
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Alliance Pharma plc disclosed greenhouse gas emissions of 50.1K tCO2e/year (Scope 1 & 2: 59 tCO2e). By scope: Scope 1: 0 tCO2e/year; Scope 2: 59 tCO2e/year; Scope 3: 50.1K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
50.1K tCO2e/year (Scope 1 & 2: 59 tCO2e)
2023
Renewable Energy
100% (UK and Germany)
of total energy
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 0 tCO2e/year |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 59 tCO2e/year |
| Scope 3 | Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.). | 50.1K tCO2e/year |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
📈 Emissions by Report Period
| Report period | Headline emissions figure reported |
|---|---|
| 2023 | 50.1K tCO2e/year (Scope 1 & 2: 59 tCO2e) |
| 2022 | 48.0K tCO2e (2022) |
Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.
✅ Reported Environmental Achievements
- 48% reduction in Scope 1 and 2 emissions (versus 2018 baseline), on track to meet interim 65% reduction target by 2025 and achieve net zero in 2030. Scope 3 emissions target set to achieve net zero by 2044 (versus 2022 baseline), with an interim reduction target of 25% by 2030.
- Nizoral™ manufacturing moved from Belgium to Thailand driving cost savings, improving on-time-in-full order delivery and reducing carbon emissions.
🎯 Climate & Sustainability Targets
🔜 Short-term
- Reduce water consumption
- Reduce waste
- Develop sustainable packaging strategy with KPIs
- Launch new packaging for Nizoral™ Derma Daily
📅 Medium-term
- Achieve 65% reduction in absolute Scope 1 and 2 emissions by 2025 (versus 2018 baseline)
- Achieve 25% reduction in absolute Scope 3 emissions by 2030 (versus 2022 baseline)
- Achieve net zero Scope 1 and 2 emissions by 2030
- Achieve 10% of Consumer Healthcare sales through products developed on our I&D platform within the next five years
🔭 Long-term
- Achieve net zero Scope 3 emissions by 2044
🌱 ESG Focus Areas
PeoplePlanetProduct